Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Gattermann

Showing results (131-140 of 158) with videos related to

Pageof 16
Sort By:
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Haematologica|December 3, 2009
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemiasMaria Domenica Cappellini, John Porter, Amal El-Beshlawy, et al.
Genome Medicine|June 20, 2014
Early aberrant DNA methylation events in a mouse model of acute myeloid leukemiaMiriam Sonnet, Rainer Claus, Natalia Becker, et al.
British Journal of Haematology|March 12, 2024
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studyAleix Noguera-Castells, Ignacio Campillo-Marcos, Veronica Davalos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating AgentsValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Leukemia Research|October 3, 2015
Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomideFabian Beier, Behzad Kharabi Masouleh, Guntram Buesche, et al.
Annals of Hematology|January 17, 2009
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic SyndromesPeter Valent, Wolf-Karsten Hofmann, Guntram Büsche, et al.
Blood|November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsHagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 16, 2007
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced diseaseManuel Aivado, Dimitrios Spentzos, Ulrich Germing, et al.
Blood|December 1, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaPhilipp le Coutre, Oliver G Ottmann, Francis Giles, et al.
Pageof 16

Showing results (131-140 of 158) with videos related to

Sort By:
Pageof 16
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Haematologica|December 3, 2009
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemiasMaria Domenica Cappellini, John Porter, Amal El-Beshlawy, et al.
Genome Medicine|June 20, 2014
Early aberrant DNA methylation events in a mouse model of acute myeloid leukemiaMiriam Sonnet, Rainer Claus, Natalia Becker, et al.
British Journal of Haematology|March 12, 2024
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studyAleix Noguera-Castells, Ignacio Campillo-Marcos, Veronica Davalos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating AgentsValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Leukemia Research|October 3, 2015
Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomideFabian Beier, Behzad Kharabi Masouleh, Guntram Buesche, et al.
Annals of Hematology|January 17, 2009
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic SyndromesPeter Valent, Wolf-Karsten Hofmann, Guntram Büsche, et al.
Blood|November 25, 2010
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsHagop M Kantarjian, Francis J Giles, Kapil N Bhalla, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 16, 2007
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced diseaseManuel Aivado, Dimitrios Spentzos, Ulrich Germing, et al.
Blood|December 1, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaPhilipp le Coutre, Oliver G Ottmann, Francis Giles, et al.
Pageof 16